Novel glucagon-like peptide-1 (GLP-1) analog (Val 8)GLP-1 results in significant improvements of glucose tolerance and pancreatic β-cell function after 3-week daily administration in obese diabetic (ob/ob) mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 2, 2006, Pages 914-921

  Green, Brian D ^a,b   Lavery, Kerry S ^a   Irwin, Nigel ^a   O'Harte, Finbarr P M ^a   Harriott, Patrick ^b   Greer, Brett ^b   Bailey, Clifford J ^c   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c ASTON UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE; INSULIN; UNCLASSIFIED DRUG; VALINE GLUCOSE LIKE PEPTIDE 1 VAL 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL FUNCTION; CELL SIZE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LONG TERM CARE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAPERITONEAL; INSULIN; INSULIN-SECRETING CELLS; ISLETS OF LANGERHANS; MALE; MICE; MICE, OBESE;

EID: 33745937115     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.097824     Document Type: Article

References (32)

1. Abramoff MD, Magelhaes PJ, and Ram SJ (2004) Image processing with ImageJ. Biophotonics Int 11:36-42.
2. Baggio LL, Huang Q, Brown TJ, and Drucker DJ (2004) A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility and glucose homeostasis. Diabetes 53:2492-2500.
3. Bailey CJ and Flatt PR (1995) Development of antidiabetic drugs, in Drugs, Diet and Disease: Mechanistic Approaches to Diabetes (Ioanides C and Flatt PR eds) pp 279-326, Ellis Horwood, London, UK.
4. Bailey CJ, Flatt PR, and Atkins TW (1982) Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int J Obes 6:11-21.
5. Bregenholt S, Moldrup A, Blume N, Karlsen AE, Nissen Friedrichsen B, Tornhave D, Knudsen LB, and Petersen JS (2005) The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem Biophys Res Commun 330:577-584.
6. Burington RS (1973) Handbook of Mathematical Tables and Formulas, McGraw-Hill Co., New York.
7. Buteau J, Roduit R, Susini S, and Prentki M (1999) Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 42:856-864.
8. Deacon CF (2004) Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53:2181-2189.
9. Deacon CF, Johnsen AH, and Holst JJ (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80:952-957.
10. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, and Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092-1100.
11. Drucker DJ (2003) Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26:2929-2940.
12. Fehmann HC, Hering BJ, Wolf MJ, Brandhorst H, Brandhorst D, Bretzel RG, Federlin K, and Goke B (1995) The effects of glucagon-like peptide-I (GLP-1) on hormone secretion from isolated human pancreatic islets. Pancreas 11:196-200.
13. Flatt PR and Bailey CJ (1981) Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 20:573-577.
14. Flint A, Raben A, Rehfeld JF, Holst JJ, and Astrup A (2000) The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Rel Metab Disord 24:288-298.
15. Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, Greer B, Flatt PR, and O'Harte FPM (2003) Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1-(7-36) amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol 31:529-540.
16. 8-substituted GLP-1 analogues. Biol Chem 385:169-177.
17. Green BD, Gault VA, O'Harte FPM, and Flatt PR (2004b) Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 10:3651-3662.
18. Green BD, Irwin N, Gault VA, Bailey CJ, O'Harte FPM, and Flatt PR (2005) Chronic treatment with exendin-(9-39)amide indicates a minor role for endogenous glucagon-like peptide-1 in metabolic abnormalities of obesity-related diabetes in ob/ob mice. J Endocrinol 185:307-317.
19. 9 substitution in glucagon-like peptide-1-(7-36) amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1-(9-36)amide and exendin-(9-39). Metabolism 53:252-259.
20. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, and Egan JM (1999) Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42:45-50.
21. Holz GG and Chepurny OG (2003) Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem 10:2471-2483.
22. Liu HK, Green BD, Gault VA McCluskey JT, McClenaghan NH, O'Harte FPM, and Flatt PR (2004) N-Acetyl-GLP-1: a DPP IV-resistant analogue of glucagon-like peptide-1 (GLP-1) with improved effects on pancreatic beta-cell-associated gene expression. Cell Biol Int 28:69-73.
23. Mark M (2003) NN-2211. Novo Nordisk. IDrugs 6:251-258.
24. Meier JJ, Nauck MA, Kranz D, Holst JJ, Deacon CF, Gaeckler D, Schmidt WE, and Gallwitz B (2004) Secretion, degradation and elimination of glucagon-like peptide-1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 53:654-662.
25. Nauck MA, Meier JJ, and Creutzfeldt W (2003) Incretins and their analogues as new antidiabetic drugs. Drug News Perspect 16:413-422.
26. Thiele TE, Van Dijk G, and Campfield LA (1997) Central infusion of GLP-1, but not leptin, produces conditioned taste aversions in rats. Am J Physiol 272:R726-R730.
27. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Heath MM, Lambert PD, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature (Lond) 379:69-72.
28. Villanueva-Penacarrillo ML, Alcantara AI, Clemente F, Delgado E, and Valverde I (1994) Potent glycogenic effect of GLP-1-(7-36) amide in rat skeletal muscle. Diabetologia 37:1163-1166.
29. Vilsboll T and Holst JJ (2004) Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 47:357-366.
30. Young AA, Gedulin BR, Bhavsar S, Bodkin N, Jodka C, Hansen B, and Denaro M (1999) Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats and diabetic rhesus monkeys (Macaca mulatta). Diabetes 48:1026-1034.
31. Zander M, Madsbad S, Madsen JL, and Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830.
32. Zhou J, Wang X, Pineyro MA, and Egan JM (1999) Glucagon-like peptide 1 and exendin-4 convert pancreatic AR42J cells into glucagon- and insulin-producing cells. Diabetes 48:2358-2366.